abstract: Extraperitoneal metastases from recurrent ovarian cancer. (study n=233 women) eg. lung, CNS, pulmonary, skin (cutaneous)

Blogger's note: requires subscription ($$$) for full text

OBJECTIVES:

To identify patterns of metastasis in patients with recurrent ovarian cancer. The influence of the route of chemotherapy administration and sequence of agents on those patterns is also examined.

RESULTS:

Thirty-five subjects developed extraperitoneal recurrent ovarian cancer, with 26 subjects (74%) after IP treatment, and 9 subjects (26%) after IV treatment. Of these extraperitoneal recurrences, 26 were in the thoracic/pulmonary cavity, 7 were within the central nervous system (CNS), and 2 were in the cutaneous (skin) tissues. The CNS and cutaneous lesions were secondary recurrences, and all occurred in subjects who had initially received IP cisplatin/paclitaxel followed by IV BEV for recurrent disease.

CONCLUSIONS:

Extraperitoneal recurrences were more common in women treated with IP chemotherapy for ovarian cancer. Specifically, women treated with IV BEV as secondary therapy after IP were at particularly high risk of extraperitoneal metastases, including in the CNS and cutaneous tissues. Physicians should be aware of the possibility of unusual metastases after the combination of IP chemotherapy and BEV, and future prospective studies of this population should carefully evaluate recurrence site patterns.

Increased Incidence of Visceral Metastases in Scottish Patients With BRCA1/2-Defective Ovarian Cancer: An Extension of the Ovarian BRCAness Phenotype

Note: see abstract for further information

Results:
Seventy-nine patients with EOC/PPC and germline BRCA1/2 mutations were identified. Fifteen had inadequate clinical data, two had carcinosarcoma, 27 had previous breast cancer, and 16 were in remission. Of the remaining 19 patients who were BRCA1/2 deficient, 14 patients (74%) developed visceral metastases compared with six (16%) of 38 patients in the control group. The percentages of liver, lung, and splenic metastases were 53%, 32%, and 32%, respectively, in the patients compared with 5%, 3%, and 5%, respectively, in the controls.
Conclusion:
Although sporadic EOC commonly remains confined to the peritoneum, BRCA1/2-deficient ovarian cancer frequently metastasizes to viscera. These data extend the ovarian BRCAness phenotype, imply BRCA1/2-deficient ovarian cancer is biologically distinct, and suggest that patients with visceral metastases should be considered for BRCA1/2 sequencing.

Toronto hospital goes global to understand cancer treatments - Healthcare in Canada - C-Health

"The research will target lung, prostate, breast, colorectal, gynecological as well as certain blood cancers."

Lung Cancer Risks Rise With Nanoparticles, Lung Cancer

Editorial comment (mine):
I had written concerning this issue before, but new info/repeat for newer members. Some years ago, I had spoken with a well known researcher while discussing family histories of ovarian cancer because in a small non-scientific study we had done, it seemed certain cancers were very prevelant and outside of what might be considered the norm. Lung cancer was one. The researcher at the time said that they believed there is was/is a genetic component between ovarian and lung cancer, aside from both being epithelial (the lining of an organ) cancers. It seems, although not specific, this article is starting to document these concerns/advances. Anyway, a FYI, but mostly it is because over years I have witnessed lung cancer patients being ostracized not only by the public by others. I hope some now take a reflective look when judging those most in need. Anyway, a bit off topic but I think it important not only for cancer communities but for all.
....................................................................................

http://www.emaxhealth.com/1075/99/31666/lung-cancer-risks-rise-nanoparticles.html

> More recent studies point to the cause of lung cancer as possibly genetic. While researchers insist environmental factors, such as smoking, asbestos exposure, etc., play a role in the development of the disease, there is growing evidence that the answer to the question is at the gene level.




Lung Cancer Risks Rise With Nanoparticles, Lung Cancer: "More recent studies point to the cause of lung cancer as possibly genetic. While researchers insist environmental factors, such as smoking, asbestos exposure, etc., play a role in the development of the disease, there is growing evidence that the answer to the question is at the gene level."